Navigation Links
Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
Date:9/24/2007

Longer Term Growth of Diabetic Neuropathy Market Will Be Driven by Launches of Disease-Modifying Therapies, According to a New Report from Decision

Resources

WALTHAM, Mass., Sept. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2016 Genentech/Roche's Lucentis and Eli Lilly's ruboxistaurin will drive the markets for the treatment of diabetic retinopathy and diabetic nephropathy.

The new Pharmacor report entitled Diabetic Complications: Retinopathy, Neuropathy, and Nephropathy finds that, over the next decade, treatment of diabetic complications will expand considerably beyond tight control of blood pressure and glucose levels. Lucentis and ruboxistaurin will come the closest to achieving blockbuster status as treatments for diabetic complications in the world's major pharmaceutical markets -- the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Additionally, although promising drug classes with potential disease-modifying activity that include PKC inhibitors and aldose reductase inhibitors have suffered a decade of setbacks and disappointing efficacy data, the report finds that longer-term market growth will be driven by several of these novel therapies.

Therapies for the painful symptoms of diabetic neuropathy will continue to dominate sales, and few patients suffering non-painful diabetic neuropathy will receive treatment until the launches of disease-modifying therapies near the midpoint of the 2006-2016 forecast period.

"The diabetic neuropathy market will experience growth during the second half of our study period because of increasing use of Pfizer's antiepileptic drug, Lyrica, and Eli Lilly's antidepressant Cymbalta, which are both approved specifically for the treatment of diabetic neuropathic pain," said Donny Wong, Ph.D., analyst at Decision Resources. "Longer term growth will also be driven by the launch of novel disease-modifying therapies such as Dainippon/Eisai/Kyorin's ranirestat and Sangamo Biosciences' SB-509."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approval For Lucentis
2. Ruboxistaurin (RBX) may prevent vision loss in diabetic patients
3. Ruboxistaurin As A Novel Treatment For Diabetic Nephropathy
4. Sleepy drivers increase road death toll
5. Traffic Violations Result in Safer Drivers
6. Dyslexia may slow a drivers reaction time as much as moderate drinking!!
7. Study suggests symptom driven therapy for adults with asthma
8. Peppermint or cinnamon smell can make drivers more alert
9. Mechanical forces drive early heart development
10. Measles Vaccination Drive Intensified In Quake-Hit Pakistan
11. More Funds Are Required For Immunisation Drive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology: